Meta-analyses demonstrate consistent benefits of SGLT-2 inhibition in terms of cardiovascular and kidney benefits without apparent heterogeneity by class overall and stratified by diabetes status [4, 5]. This evidence concerns the gene SLC5A2 and diabetes mellitus.